Maze Therapeutics, Inc.

Maze Therapeutics, Inc. (MAZE) priced its initial public offering on Jan 31, 2025 at $16.00 per share, within its $15.00–$17.00 range, raising $140M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $700.4M. J.P. Morgan was lead-left underwriter, joined by TD Cowen, Leerink Partners and Guggenheim. Fenwick & West advised the company and Davis Polk advised the underwriters.

Status

IPO

Ticker

MAZE

Exchange

Nasdaq Global Market

Priced

Jan 31, 2025

IPO price

$16.00

Price range

$15.00–$17.00

Raised

$140M

Market cap at IPO price

$700.4M

First filed

Jan 7, 2025

Underwriters

J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim

Company counsel

Fenwick & West

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.